* Meta-terms correspond to biological or medical specialty concerned with one or more keywords (or keywords hierarchies), qualifiers, or resource types. Other terms also benefit from this structure, when the topic warrants it, eg education. See the list.

Doc'CISMeF search for this specility :


Preferred Label : gastroenterology;

Obsolete resource : false;

True Meta (CISMeF) : true;

Details


Main resources

You can consult :


https://www.chu-lyon.fr/hepatite-auto-immune-hai
2025
France
patient education handout
chronic active hepatitis
hepatitis, autoimmune

---
https://ansm.sante.fr/tableau-marr/lutecium-177lu-oxodotreotide
2025
false
false
false
France
French
lutetium Lu 177 dotatate
risk management
patients guideline
lutetium Lu 177 dotatate
infusions, intravenous
radiotherapy
radiopharmaceuticals
radiopharmaceuticals
neuroendocrine tumors
lutetium (177Lu) oxodotreotide
drug information
organometallic compounds
octreotide
octreotide
organometallic compounds
octreotide

---
https://www.has-sante.fr/jcms/p_3576306/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2025
false
false
false
France
evaluation of the transparency committee
olaparib
cancer
Imfinzi
endometrial neoplasms
durvalumab
Lynparza
endometrium
neoplasm, malignant
olaparib
association
olaparib
durvalumab
Endomet

---
https://www.has-sante.fr/jcms/p_3576200/fr/iqirvo-elafibranor-cholangite-biliaire-primitive-cbp
2025
false
false
false
France
drug therapy, combination
evaluation of the transparency committee
cholangitis
elafibranor
Primary Biliary Cholangitis

---
https://www.has-sante.fr/jcms/p_3576557/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
adult
Fluoropyrimidine
platinum salt, nos
Gastric Adenocarcinoma
stomach neoplasms
Gastroesophageal Junction Adenocarcinoma
esophageal neoplasms
HER2/Neu Negative
CLDN18.2 Positive
infusions, intravenous
zolbetuximab
evaluation of the transparency committee
zolbetuximab
adenocarcinoma

---
https://www.has-sante.fr/jcms/p_3576262/fr/jakavi-ruxolitinib-maladie-du-greffon-pediatrie
2025
false
false
false
France
administration, oral
pharmaceutical solutions
graft vs host disease
child
ruxolitinib
Janus Kinase Inhibitors
evaluation of the transparency committee
ruxolitinib

---
https://www.has-sante.fr/jcms/p_3577036/fr/kalydeco-ivacaftor-mucoviscidose
2025
false
false
false
France
infant
treatment outcome
insurance, health, reimbursement
administration, oral
ivacaftor
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://sesstim.univ-amu.fr/fr/video-box/seminaire-interne-clemence-ramier
2025
France
audiovisual aids
persons
type b viral hepatitis
behavior, nos
hepatitis B, chronic
chronic hepatitis, nos
neoplasm, malignant
liver neoplasms
behavior
cancer of liver

---
https://www.omedit-centre.fr/medias/Securiser-administration-insulines.pdf
2025
France
scientific and technical information
administration
insulins
organization and administration
administration of insulin

---
https://www.chu-lyon.fr/maladies-vasculaires-du-foie
2025
France
popular works
liver diseases
vascular diseases
vascular disease, nos
disease of liver, nos

---
https://www.cochrane.org/fr/CD014845/CENTRALED_letiquetage-calorique-energetique-peut-il-modifier-la-selection-et-la-consommation-daliments-ou
2025
United Kingdom
review of literature
french abstract
eating
eating, nos
food preferences
food, nos
alcohol drinking
breeding
ethyl alcohol

---
https://www.has-sante.fr/jcms/p_3586458/fr/kayfanda-odevixibat-traitement-du-prurit-cholestatique-associe-au-syndrome-d-alagille
2025
false
false
false
France
Odevixibat sesquihydrate (substance)
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
infant
child
adult
administration, oral
treatment outcome
insurance, health, reimbursement
odevixibat
evaluation of the transparency committee
pruritus
odevixibat
alagille syndrome

---
https://www.inspq.qc.ca/publications/3603
2025
Canada
technical report
quebec
diarrhea, nos
diarrhoea
Clostridioides difficile
diarrhea

---
https://www.has-sante.fr/jcms/p_3587094/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
Locally Advanced Cholangiocarcinoma
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
ivosidenib
adult
Metastatic Cholangiocarcinoma
IDH1 NP_005887.2:p.R132X
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
administration, oral
antineoplastic agents
evaluation of the transparency committee
ivosidenib

---
https://www.cochrane.org/fr/CD014889/CENTRALED_est-il-benefique-de-garder-la-veine-azygos-intacte-pendant-une-chirurgie-pour-les-nouveau-nes
2025
United Kingdom
review of literature
french abstract
operative procedure, nos
azygous vein
disease
infant, newborn
esophageal atresia
general surgery
azygos vein
newborn, nos
congenital atresia of esophagus

---
https://www.has-sante.fr/jcms/p_3588817/fr/iqirvo-elafibranor-cholangite-biliaire-primitive
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
Primary Biliary Cholangitis
drug therapy, combination
ursodeoxycholic acid
adult
elafibranor
evaluation of the transparency committee
elafibranor

---
https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
durvalumab
antineoplastic combined chemotherapy protocols
Mismatch Repair Deficiency
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
infusions, intravenous
evaluation of the transparency committee
durvalumab
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3591345/fr/relistor-bromure-de-methylnaltrexone-constipation-liee-aux-opioides
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
methylnaltrexone bromide
injections, subcutaneous
adult
evaluation of the transparency committee
Opioid-Induced Constipation
methylnaltrexone
naltrexone methylbromide

---
https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
insurance, health, reimbursement
treatment outcome
Antineoplastic Agents, Immunological
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Mismatch Repair Proficient
Mismatch Repair Deficiency
durvalumab
durvalumab
olaparib
olaparib
evaluation of the transparency committee
endometrial neoplasms

---
https://ansm.sante.fr/tableau-marr/tremelimumab
2025
false
false
false
France
French
tremelimumab
tremelimumab
risk management
drug information
patient education handout
Immune-Mediated Adverse Reaction
Drug-Related side effects and adverse reactions
signs and symptoms
Drug-Related side effects and adverse reactions

---
https://www.cochrane.org/fr/CD014999/CENTRALED_l-embolisation-transarterielle-prophylactique-obstruction-des-vaisseaux-sanguins-par-precaution-est
2025
United Kingdom
review of literature
french abstract
endoscopes
hemorrhage, nos
peptic ulcer
obstruction, nos
endoscopy, nos
gastric ulcer, nos
stomach ulcer
blood vessels
stomach
hemorrhage
peptic ulcer, nos
attentiveness
tube, nos
bloodletting
endoscope, nos
endoscopy

---
https://www.has-sante.fr/jcms/p_3594155/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
stomach neoplasms
esophageal neoplasms
treatment outcome
insurance, health, reimbursement
zolbetuximab
infusions, intravenous
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
CLDN18.2 Positive
HER2/Neu Negative
evaluation of the transparency committee
adenocarcinoma
zolbetuximab
esophagogastric junction

---
https://ansm.sante.fr/informations-de-securite/emblaveo-aztreonam-avibactam-1-5-g-0-5-g-poudre-pour-solution-a-diluer-pour-perfusion-risque-potentiel-de-flacons-fissures-ou-casses
2025
false
false
false
France
French
pharmacovigilance note

---
https://www.cochrane.org/fr/CD000478/CENTRALED_lazathioprine-et-la-6-mercaptopurine-sont-elles-efficaces-pour-le-traitement-de-la-rectocolite
2025
United Kingdom
review of literature
french abstract
azathioprine
hemorrhage, nos
Mercaptopurine
mercaptopurine
azathioprine
proctocolitis, nos
colitis, ulcerative

---
https://ansm.sante.fr/actualites/aggravation-des-tensions-en-pegasys-nouvelles-mesures-et-referentiel-actualise
2025
false
false
false
France
French
peginterferon alfa-2a
drug information
Ropeginterferon Alfa-2B
guideline
popular works

---
https://minerva-ebp.be/Theme/Analysis/897
2025
Belgium
critical appraisal or critical reading
eating, nos
mortality
consumer organizations
eating
Food, Ultra-Processed
food, nos

---
https://www.has-sante.fr/jcms/p_3598458/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible-ou-ultra-faible
2025
false
false
false
France
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
trastuzumab

---
https://www.inspq.qc.ca/publications/3632
2025
Canada
technical report
diarrhoea
diarrhea
Clostridioides difficile
diarrhea, nos
organization and administration
quebec

---
https://www.ema.europa.eu/en/medicines/human/EPAR/apexelsin
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
paclitaxel
paclitaxel

---
https://www.ema.europa.eu/en/medicines/human/EPAR/wezenla
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Ustekinumab
Ustekinumab
biosimilar pharmaceuticals

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/guide-dusage-optimal-pour-le-traitement-de-la-diarrhee-ou-de-la-colite-associee-a-clostridium-difficile.html
2025
Canada
practice guideline
diarrhoea
colitis, nos
diarrhea, nos
Handbook
clostridium
Clostridioides
clostridium difficile
colitis
diarrhea

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
zolbetuximab
zolbetuximab
orphan drug production

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kayfanda
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
odevixibat
odevixibat

---
https://www.ema.europa.eu/en/medicines/human/EPAR/iqirvo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
administration, oral
elafibranor
elafibranor
orphan drug production

---
https://www.has-sante.fr/jcms/p_3602225/fr/in-pact-018
2025
France
health technology assessment
paclitaxel
flatulence
tympanites
paclitaxel

---
https://beh.santepubliquefrance.fr/beh/2025/8/2025_8_1.html
2025
France
journal article
public health
eating
research report
albumin/globulin ratio
french
adult
nutrition guidelines
france
resulting in
recommended dietary allowances
adulthood

---
https://ansm.sante.fr/tableau-acces-derogatoire/avastin-r-25-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
Bevacizumab
drug information
guidelines for drug use
intravitreal injections
macular degeneration
Neovascular age-related macular degeneration

---
https://www.chu-lyon.fr/eduhepat-etp-maladie-hepatique-chronique
2025
France
patient education handout
therapeutics
chronic disease, nos
disease
education
disease of liver, nos
patient education as topic
chronic disease
liver diseases
has patient

---
https://www.chu-lyon.fr/etp-lift-liyon-foie-transition
2025
France
patient education handout
Bridge Therapy
chronic disease
disease of liver, nos
education
liver
has patient
disease
chronic disease, nos
liver diseases
patient education as topic

---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2025
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
antineoplastic combined chemotherapy protocols

---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2025
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
graft vs host disease
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease
pharmaceutical solutions
child
guidelines for drug use
summary of product characteristics
package leaflet
tablets

---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local

---
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular
carcinoma, non-small-cell lung
small cell lung carcinoma
bronchial neoplasms

---
https://ansm.sante.fr/actualites/amoxicilline-des-recommandations-pour-contribuer-a-garantir-la-couverture-des-besoins-des-patients
2025
false
false
false
France
French
amoxicillin
guidelines for drug use
amoxicillin
administration, oral
infant
child
amoxicillin
amoxicillin-potassium clavulanate combination
amoxicillin-potassium clavulanate combination
amoxicillin and beta-lactamase inhibitor

---
https://ansm.sante.fr/tableau-acces-derogatoire/lutathera
2025
false
false
false
France
French
infusions, intravenous
drug information
lutetium (177Lu) oxodotreotide
lutetium Lu 177 dotatate
radiopharmaceuticals
guidelines for drug use
Pheochromocytoma-paraganglioma
pheochromocytoma
Metastatic Lung Neuroendocrine Tumor
bronchial neoplasms
neoplasm metastasis
Thymic neuroendocrine tumor
neuroendocrine tumors
thymus neoplasms
Metastatic Thymus Neuroendocrine Neoplasm
meningioma
Somatostatin Receptor Positive
Somatostatin Receptor 2 Positive
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7
technical report

---
https://www.has-sante.fr/jcms/p_3574834/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
evaluation of the transparency committee
ivosidenib
ivosidenib
biliary tract, nos
neoplasm, malignant
Tibsovo
biliary tract neoplasms
biliary tract cancer

---
https://www.anses.fr/fr/content/complements-alimentaires-aliments-enrichis-sportifs
2024
France
popular works
risk
eating, nos
Dietary Supplement
Enriched Food
food, nos
eating
dietary supplements
athletes
food, fortified
infant nutritional physiological phenomena
Food Consumption
Fortified Food

---
https://ansm.sante.fr/tableau-acces-derogatoire/bylvay
2024
false
false
false
France
French
insurance, health, reimbursement
odevixibat
odevixibat
summary of product characteristics
package leaflet
guidelines for drug use
infant
child
pruritus
cholestatic pruritus in Alagille syndrome
alagille syndrome

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib

---
https://www.has-sante.fr/jcms/p_3478084/fr/zepatier-elbasvir/grazoprevir-hepatite-c-chez-les-adolescents-a-partir-de-12-ans
2024
false
false
false
France
evaluation of the transparency committee
adolescence
Hepatitis C Virus
hepatitis C
viral hepatitis c
Elbasvir/Grazoprevir
adolescent
Zepatier
Autonomic Nervous System
Teenager
Twelve
elbasvir-grazoprevir drug combination
Adolescents
Adolescent
Hepatitis C Infection
Algeria

---
https://www.has-sante.fr/jcms/p_3478096/fr/kalydeco-ivacaftor-mucoviscidose
2024
false
false
false
France
infant
child
evaluation of the transparency committee
ivacaftor
cystic fibrosis
ivacaftor
Ivacaftor
Cystic Fibrosis
cystic fibrosis
kalydeco
ivacaftor

---
https://www.has-sante.fr/jcms/p_3490351/fr/lytgobi-futibatinib-cholangiocarcinome
2024
false
false
false
France
futibatinib
treatment outcome
insurance, health, reimbursement
adult
Intrahepatic Cholangiocarcinoma
antineoplastic agents
Locally Advanced Intrahepatic Cholangiocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
Cancer Progression
administration, oral
evaluation of the transparency committee
cholangiocarcinoma
futibatinib

---
https://www.has-sante.fr/jcms/p_3490839/fr/cufence-trientine-dichlorhydrate-maladie-de-wilson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
chelating agents
trientine
adult
adolescent
child
evaluation of the transparency committee
trientine hydrochloride
hepatolenticular degeneration
trientine

---
https://ansm.sante.fr/tableau-acces-derogatoire/itraconazole
2024
false
false
false
France
French
itraconazole
guidelines for drug use
administration, oral
tinea
child
microsporum
antifungal agents
itraconazole
continuity of patient care

---
https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information Documentation
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety or Other Trial Information Documentation
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
Pregnant People
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida

---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib

---
https://ansm.sante.fr/tableau-marr/adalimumab
2024
false
false
false
France
French
Adalimumab
risk management
continuity of patient care
drug information
adult
child
patient education handout

---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma

---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab

---
https://ansm.sante.fr/tableau-marr/tacrolimus
2024
false
false
false
France
French
risk management
tacrolimus
tacrolimus
administration, oral
guidelines for drug use
patient education handout
continuity of patient care
immunosuppressive agents

---
https://ansm.sante.fr/tableau-acces-derogatoire/lynparza-100-mg-et-150-mg-comprimes-pellicules
2024
false
false
false
France
French
drug information
olaparib
administration, oral
olaparib
breast neoplasms
HER2-Negative Breast Carcinoma

---
https://ansm.sante.fr/tableau-acces-derogatoire/pegasys
2024
false
true
false
France
French
drug information
insurance, health, reimbursement
peginterferon alfa-2a
technical report
myeloproliferative disorders

---
https://ansm.sante.fr/tableau-acces-derogatoire/kaftrio-75-mg-50-mg-100-mg-comprime-pellicule-kalydeco-150-mg-comprime-pellicule
2024
false
false
false
France
French
cystic fibrosis
guidelines for drug use
continuity of patient care
drug therapy, combination
administration, oral
ivacaftor, tezacaftor and elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
elexacaftor
adult
adolescent
ivacaftor
trikafta
drug combinations
drug information

---
https://www.ema.europa.eu/en/medicines/human/EPAR/libmyris
2024
false
false
false
Netherlands
French
English
Adalimumab
Adalimumab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
biosimilar pharmaceuticals
drug approval
europe
injections, subcutaneous
drug interactions
pregnancy
breast feeding
arthritis, psoriatic
psoriasis
hidradenitis suppurativa
crohn disease
panuveitis
arthritis, rheumatoid
colitis, ulcerative
uveitis, posterior
uveitis, intermediate
Chronic anterior uveitis (disorder)
spondylitis, ankylosing
arthritis, juvenile
adalimumab
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor Inhibitors

---
https://ansm.sante.fr/tableau-marr/atezolizumab
2024
false
false
false
France
French
atezolizumab
atezolizumab
atezolizumab
Drug-Related side effects and adverse reactions
risk management
drug information
patient education handout
Drug-Related side effects and adverse reactions
signs and symptoms
antineoplastic agents
antineoplastic agents
immune system diseases
immune system diseases
antibodies, monoclonal
antibodies, monoclonal

---
https://ansm.sante.fr/tableau-marr/pembrolizumab
2024
false
false
false
France
French
risk management
pembrolizumab
Infusion related reaction
immune system diseases
Drug-Related side effects and adverse reactions
patient education handout
pregnancy
continuity of patient care
drug monitoring
Antineoplastic Agents, Immunological
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized

---
https://ansm.sante.fr/tableau-marr/sulfate-de-sodium-anhydre-sulfate-de-magnesium-heptahydrate-sulfate-de-potassium
2024
false
false
false
France
French
risk management
guidelines for drug use
package leaflet
patients guideline
drug combinations
colonoscopy
cathartics
administration, oral
magnesium sulfate
potassium sulfate
sodium sulfate
magnesium sulfate, heptahydrate

---
https://ansm.sante.fr/informations-de-securite/alofisel-darvadstrocel-retrait-du-marche-de-lunion-europeenne-en-raison-de-labsence-de-demonstration-dun-benefice-clinique-suffisant-justifiant-le-maintien-de-son-utilisation
2024
false
false
false
France
French
Safety-Based drug withdrawals
pharmacovigilance note
Darvadstrocel
europe
risk assessment
mesenchymal stem cell transplantation

---
https://ansm.sante.fr/tableau-marr/maralixibat
2024
false
false
false
France
French
risk management
maralixibat
maralixibat chloride
guidelines for drug use
patient education handout
medication errors

---
https://ansm.sante.fr/tableau-marr/acide-cholique
2024
false
false
false
France
French
cholic acid
risk management
guideline
cholic acid
administration, oral
bile acid synthesis defect, congenital, 2
bile acid synthesis defect, congenital, 1
signs and symptoms
drug information
bile acid synthesis defect, congenital, 2
bile acid synthesis defect, congenital, 1

---
https://www.has-sante.fr/jcms/p_3497062/fr/iomeron-iomeprol-produit-de-contraste-iode
2024
false
false
false
France
evaluation of the transparency committee
iodine, nos
iomeprol
contrast media
iomeprol
Iomeprol
iomeron
iomeprol
iodine

---
https://www.fcvd.fr/wp-content/uploads/2024/02/Information-avant-la-realisation-d-une-sphincterotomie-pour-fissure-anale.pdf
2024
France
patient education handout
achievement
fissure in ano
Anal Fissure, CTCAE
Sphincterotomy
No Information Available
anal fissure

---
https://www.fcvd.fr/wp-content/uploads/2024/02/Informations-avant-la-realisation-d-une-cure-chirurgicale-de-prolapsus-rectal-exteriorise-selon-Altemeier.pdf
2024
France
patient education handout
Continuing Umbrella of Research Experience for Underserved Minorities (CURE) Program
Informed
rectal prolapse
Oprelvekin
Cure Study
Rectal Prolapse
exteriorization
No Information Available
Tiaprofenic Acid
Expedited Report
Informative
achievement
rectal prolapse

---
https://www.fcvd.fr/wp-content/uploads/2024/02/Informations-avant-la-realisation-d-une-cure-de-fistule-anale-par-fistulotomie.pdf
2024
France
patient education handout
No Information Available
Cure Study
Oprelvekin
anal fistula
Informed
Anus Fistula, CTCAE
rectal fistula
incision of anal fistula
Informative
Continuing Umbrella of Research Experience for Underserved Minorities (CURE) Program
Anorectal Fistula
achievement
anal fistula

---
https://www.has-sante.fr/jcms/p_3497047/fr/xerava-eravacycline-tetracyclines
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
eravacycline
Complicated intra-abdominal infection
complicated intra-abdominal infections
infusions, intravenous
adult
xerava
anti-bacterial agents
Product containing only eravacycline in parenteral dose form (medicinal product form)
evaluation of the transparency committee
tetracyclines
eravacycline

---
https://www.has-sante.fr/jcms/p_3497065/fr/visipaque-iodixanol-produit-de-contraste-iode
2024
false
false
false
France
iodixanol
-
-
evaluation of the transparency committee
iodine
iodixanol
contrast media

---
https://www.has-sante.fr/jcms/p_3497029/fr/xenetix-iobitridol-produit-de-contraste-iode
2024
false
false
false
France
iobitridol
evaluation of the transparency committee
contrast media
iodine
iobitridol

---
https://www.has-sante.fr/jcms/p_3498127/fr/dificlir-fidaxomicine-infection-a-clostridium-difficile
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
fidaxomicin
tablets
adult
anti-bacterial agents
time
evaluation of the transparency committee
Fidaxomicin
clostridium infections
Clostridium difficile Infections

---
https://www.has-sante.fr/jcms/p_3415645/fr/qinlock-ripretinib-tumeurs-stromales-gastro-intestinales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Advanced Gastrointestinal Stromal Tumor
Refractory Malignant Gastrointestinal Stromal Tumor
antineoplastic agents
ripretinib
administration, oral
evaluation of the transparency committee
gastrointestinal stromal tumors
ripretinib

---
https://www.has-sante.fr/jcms/p_3468175/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2024
false
false
false
France
Cisplatin/Durvalumab/Gemcitabine Regimen
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
cisplatin
Gemcitabine
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
durvalumab
adult
guidelines for drug use
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
durvalumab

---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell

---
https://www.has-sante.fr/jcms/p_3500260/fr/livmarli-maralixibat-syndrome-d-alagille
2024
false
false
false
France
Cholestatic pruritus (disorder)
treatment outcome
insurance, health, reimbursement
infant
child
administration, oral
pharmaceutical solutions
maralixibat chloride
Maralixibat Chloride
cholestatic pruritus in Alagille syndrome
evaluation of the transparency committee
alagille syndrome
maralixibat

---
https://www.has-sante.fr/jcms/p_3500210/fr/bylvay-odevixibat-prurit-cholestatique-associe-au-syndrome-d-alagille
2024
false
false
false
France
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
treatment outcome
insurance, health, reimbursement
child
infant
administration, oral
odevixibat
evaluation of the transparency committee
odevixibat
alagille syndrome

---
https://www.inrs.fr/publications/bdd/eficatt/fiche.html?refINRS=EFICATT_Infections%20%C3%A0%20bact%C3%A9ries%20multir%C3%A9sistantes%20(BMR)%20digestives
2024
France
scientific and technical information
bacterium, nos
digestive tract function, nos
bacteria
gastrointestinal agents
digestion
digestants
digestant, nos
Basal Metabolic Rate
Percent of Bacteria
infectious disease, nos
Bacteria
Bacterial Count
Bacteria Present
Digestion
Infections
Infection

---
https://www.cochrane.org/fr/CD012608/LIVER_la-modification-de-lapport-en-graisses-alimentaires-est-elle-benefique-ou-risquee-pour-les-personnes
2024
United Kingdom
review of literature
french abstract
Dietary Route of Administration
gallstones
Modification
Alteration
Cholelithiasis
dietary fats
What Month is it
risk
Amendment
grease, nos
Amendment Regulatory Submission
biliary calculus, nos
persons
Data Change Date
Bile Duct Stone
People

---
https://www.has-sante.fr/jcms/p_3500938/fr/ultravist-iopromide-produit-de-contraste-iode
2024
false
false
false
France
evaluation of the transparency committee
iopromide
iodine
contrast media

---
https://www.inrs.fr/media.html?refINRS=QR%20181
2024
France
journal article
Involvement
risk
Hepatitis C Virus Positive
disease
hepatitis, nos
Fix
What Month is it
Disease Transmission
hepatitis
Hepatitis

---
https://www.cochrane.org/fr/CD012609/GUT_infliximab-pour-le-maintien-dun-traitement-efficace-dans-la-maladie-de-crohn
2024
United Kingdom
review of literature
french abstract
Treatment
Therapy Object
No Treatment for Diabetes
Infliximab
GDC Treatment Frequency Terminology
Until Effective
crohn disease
Maintenance
Infliximab Given for Kawasaki Disease
On Treatment
Treatment Study
Treatment Epoch
Infliximab
crohn's disease, nos
During Treatment
Treat
Biomaterial Treatment
Crohn Disease

---
https://dumas.ccsd.cnrs.fr/dumas-04492639
2024
France
dissertations, academic
patient escort service
counseling
crohn disease
has patient
Questionnaire Not Completed Due to Patient Illness
Crohn Disease
Transjugular Intrahepatic Portosystemic Shunt
crohn's disease, nos
disease

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab

---
https://www.cochrane.org/fr/CD015084/GUT_prebiotiques-pour-le-traitement-de-la-rectocolite-hemorragique
2024
United Kingdom
review of literature
french abstract
On Treatment
prebiotics
GDC Treatment Frequency Terminology
No Treatment for Diabetes
Treatment Epoch
hemorrhage, nos
Proctocolitis
colitis, ulcerative
Treatment Study
Treatment
Biomaterial Treatment
Hemorrhage
During Treatment
Therapy Object
proctocolitis, nos
Treat

---
https://www.has-sante.fr/jcms/p_3471694/fr/orkambi-lumacaftor/ivacaftor-mucoviscidose
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumacaftor, ivacaftor drug combination
drug combinations
ivacaftor
lumacaftor
ivacaftor and lumacaftor
infant
administration, oral
evaluation of the transparency committee
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate

---
https://www.has-sante.fr/jcms/p_3508868/fr/acide-tranexamique-tillomed-acide-tranexamique-antifibrinolytique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intravenous
adult
adolescent
child
hemorrhage
hemorrhage due to fibrinolysis
drugs, generic
tranexamic acid
evaluation of the transparency committee
antifibrinolytic agents
tranexamic acid

---
https://ansm.sante.fr/tableau-marr/darvadstrocel
2024
false
false
false
France
French
risk management
Darvadstrocel
darvadstrocel
guidelines for drug use
guideline
medication errors
Darvadstrocel
drug storage
Infections
cold chain
temperature recording

---
https://ansm.sante.fr/actualites/campagne-vaccinale-contre-les-infections-a-papillomavirus-humains-hpv-les-donnees-recueillies-apres-la-premiere-dose-confirment-le-profil-de-securite-du-vaccin-gardasil-9
2024
false
false
false
France
French
papillomavirus vaccines
papillomavirus infections
vaccine safety
Human Papillomavirus Recombinant Vaccine nonavalent
mass vaccination
Vaccination Campaign
technical report
adolescent
vaccination

---
https://ansm.sante.fr/actualites/decision-du-06-05-2024-renouvellement-du-cpc-du-medicament-imfinzi-durvalumab-50-mg-ml-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
drug information
durvalumab

---
https://www.has-sante.fr/jcms/p_3506840/fr/imfinzi-durvalumab-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
evaluation of the transparency committee
Imfinzi
Durvalumab
durvalumab
durvalumab

---
https://www.anses.fr/fr/content/ingestion-accidentelle-medicaments-chevaux
2024
France
popular works
ingestion
Amonafide Dihydrochloride
ingestion
equine species
horses
Accidental Drug Ingestion
pharmaceutical preparations
attentiveness
Horse
eating
drug, nos

---
https://www.cochrane.org/fr/CD015038/COLOCA_medicaments-qui-tuent-les-bacteries-antibiotiques-ou-chirurgie-quest-ce-qui-est-le-plus-efficace
2024
United Kingdom
review of literature
french abstract
Bacteria
Appendicitis, CTCAE
Surgical Procedure
What Month is it
appendicitis, nos
GDC Therapeutic Agent Terminology
drug, nos
Overdenture
antibiotic, nos
Surgical Procedure was Curative Therapy
bacterium, nos
appendicitis
Bacteria Present
Limburgish Language
Antibiotic
antibiotics
Until Effective
Percent of Bacteria
appendicitis
Treat
anti-bacterial agents
general surgery
bacteria
Medication
Bacterial Count
Appendicitis
operative procedure, nos

---
https://www.has-sante.fr/jcms/p_3517566/fr/kaftrio-ivacaftor/tezacaftor/elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-de-2-ans-a-moins-de-6-ans
2024
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
drug combinations
drug therapy, combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
administration, oral
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://www.has-sante.fr/jcms/p_3517160/fr/tecentriq-atezolizumab-oncologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing only atezolizumab in parenteral dose form (medicinal product form)
atezolizumab
antineoplastic combined chemotherapy protocols
Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen
neoplasm metastasis
carcinoma, non-small-cell lung
small cell lung carcinoma
Extensive Stage Lung Small Cell Carcinoma
antineoplastic agents
Unresectable Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
carcinoma, hepatocellular
evaluation of the transparency committee
atezolizumab

---
https://www.has-sante.fr/jcms/p_3518114/fr/revestive-teduglutide-syndrome-du-grele-court-chez-l-adulte
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
teduglutide
gastrointestinal agents
evaluation of the transparency committee
adult
teduglutide
short bowel syndrome

---
https://www.sfed.org/wp-content/uploads/2024/04/Recommandations-Antibioprophylaxie-en-endoscopie-digestive_nov23.pdf
2024
France
practice guideline
Antibiotic Prophylaxis
endoscopy, nos
digestant, nos
Digestion
digestive tract function, nos
Endoscopic Procedure
antibiotic prophylaxis
endoscopy, digestive system

---
https://pap-pediatrie.fr/hepato-gastro/ingestion-de-corps-etranger-chez-lenfant
2024
France
scientific and technical information
algorithms
foreign body, nos
Child Relation
child, nos
foreign body, nos
ingestion
foreign bodies
Foreign Body Ingestion
ingestion
child
Child Individual
body parts
eating

---
https://www.anses.fr/fr/content/petit-dejeuner-diner-quelle-repartition-des-prises-alimentaires-journee
2024
France
popular works
Between Lunch and Dinner
What Month is it
eating
Breakfast
dinner time
Dietary Route of Administration
breakfast
dinner
Before Breakfast

---
https://www.has-sante.fr/jcms/p_3519904/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2024
false
false
false
France
antineoplastic combined chemotherapy protocols
endometrial neoplasms
evaluation of the transparency committee
durvalumab
olaparib

---
https://www.cochrane.org/fr/CD011670/COLOCA_ablation-chirurgicale-precoce-ou-differee-de-lappendice-quelle-est-la-meilleure-solution-pour
2024
United Kingdom
review of literature
french abstract
What Month is it
Appendix
Appendage
solution, nos
solutions
mace
Ablation Therapy
appendectomy
mass, nos
Treat
Appendix Mass
excision, nos
with size
Solution Dosage Form Category
Murine Appendix
Tiaprofenic Acid
Resolution

---
https://minerva-ebp.be/FR/Article/2380
2024
France
critical appraisal or critical reading
Caffeine Not Routinely Consumed
Treatment Epoch
Negation
Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis
Patient was not Postmenopausal with no Prior Oophorectomy
No Treatment for Diabetes
EWS Off Protocol Therapy/Study Table
No History of Neonatal Complication
Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
On Treatment
Cancer History Absent
Medication Not Taken
Case
Fluorescence In Situ Hybridization Was Not Performed
Therapy Object
Stayed the Same
Treatment Study
Not Lost to Follow-Up
Breast Cancer Anti-Estrogen Resistance Protein 1
Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
Lymph Node Dissection Was Not Performed
Tumor Reoccurrence Absent After Initial Treatment
Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered
AML Off Protocol Therapy/Study Table
Radiation History Negative
Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed
symptom, nos
ROS1 Rearrangement Analysis Was Not Performed
First Degree Family History Thyroid Cancer Negative
Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection
IV Anesthesia was not Administered
New Disease is not Multifocal
Has No Sibling
Preservation
ALK Rearrangement Analysis Was Not Performed
Nitric Oxide
ATRX Gene Mutation Negative
Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up
Use of Smokeless Tobacco at Time of Diagnosis Negative
Conservation
No History of Myopathy
No Cases Transmission Pattern
EGFR Mutation Analysis Was Not Performed
Paraneoplastic Syndrome is Not Present
Complication
gallstones
No History of Rheumatic Fever
MGMT Promoter Methylation Testing Was Not Performed
Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered
No History of Gestational Complication
Any Metastatic Diagnosis Absent
Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
No Known History of Illicit Drug Use
Symptomatic Presentation
Treat
Routine Cytogenetics Were not Completed
Additional Surgery for New Metastatic Tumor Event Was Not Performed
Bile Duct Stone
BRAF Mutation Analysis Was Not Performed
Symptomatic Therapy
EGFR Amplification Analysis Was Not Performed
During Treatment
Unemployed
No History of Kawasaki Disease
First Degree Family History of Primary Brain Tumor Negative
Nitric Oxide Measurement
Preoperative IV Antacids were not Administered
snacks
Additional Molecular Studies Were Not Performed
Regular Smokeless Tobacco Use for Six Weeks or More Negative
No History of Other Muscular Dystrophy or Glycogen Storage Disorder
CTNND1 wt Allele
Neither Case or Control Status
Preservation Procedure
Another Form of Birth Control was not Used
Interferon Gamma Treatment was not Administered Prior to Specimen Resection
EGFR Gene Amplification Negative
BCAR1 wt Allele
RET Rearrangement Analysis Was Not Performed
complication, nos
Preoperative IV Sedation was Not Administered
Documentation Absent
Preoperative IV Opiates were not Administered
History of Medical Treatment Absent
No Known History of Alcohol Use
Adjuvant Post-operative Chemotherapy Was Not Administered
Other Preoperative IV Medications were not Administered
Norway
GDC Treatment Frequency Terminology
Chemical/Occupational Exposure Absent
Hypertension Absent
KRAS Mutation Analysis Was Not Performed
Can
Additional Surgery for New Tumor Event Absent
NON Mouse
Minor Criteria for Rheumatic Heart Disease Not Present
Evidence of Disease Absent after Completion of Therapy
Complicating
Conservative Treatment
NRAS Mutation Analysis Was Not Performed
Patient was Not Previously Evaluated for Current Chief Complaint
NF1 Mutation Analysis Was Not Performed
No History of Non-Cardiac Surgery
Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed
ATRX Mutation Analysis Was Not Performed
PTEN Mutation Analysis Was Not Performed
Therapeutic Ionizing Radiation to Head History Absent
Preoperative IV Antiemetics were not Administered
Family History of Stomach Cancer Absent
Radiation Therapy Not Received
10q23/PTEN Locus Deletion Analysis Was Not Performed
KIT Mutation Analysis Was Not Performed
New Tumor Event After Initial Treatment Absent
biliary calculus, nos
No Response to Intervention for Kawasaki Disease
Tumor Progression Absent After Initial Treatment
Additional Immunohistochemistry Was Not Performed
Biomaterial Treatment
History of Colorectal Cancer Negative
Options
TP53 Mutation Analysis Was Not Performed
Cholelithiasis
Adjuvant Post-operative Immunological Therapy Was Not Administered
BRAF Rearrangement Analysis Was Not Performed
No History of Congenital Heart Disease
MET Mutation Analysis Was Not Performed
True Case Status
Chemotherapy Not Received
Case Dosing Unit
Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Catenin Delta-1
Neither
Adjuvant I-131 Therapy Negative
PDGFRA Mutation Analysis Was Not Performed
Local Anesthesia Agents were not Administered
ERBB2 Mutation Analysis Was Not Performed
SDH Complex Mutation Analysis Was Not Performed
IDH Family Mutation Analysis Was Not Performed
Regional Anesthesia was not Administered
Chief Complaint was Not Witnessed
Treatment
IDH Family Wildtype
First Degree Family History Cancer Negative
Chief Complaint Not Caused by Trauma
Adjuvant Post-operative Radiation Therapy Was Not Administered
Optional
Intercurrent Illness is Absent at Onset of Chief Complaint
Physician Diagnosed Diabetes Absent
1p/19q Deletion Analysis Was Not Performed
Radiation Was Not Administered as an Additional Treatment for a New Tumor Event
Intervention Not Given for Kawasaki Disease
Coronavirus Anxiety Scale
Additional Surgery for New Loco-Regional Tumor Event Was Not Performed
PTEN Gene Mutation Negative
Packaging Case

---
https://www.has-sante.fr/jcms/p_3519075/fr/sensura-mio
2024
France
health technology assessment
digestant, nos
Interferon Gamma Treatment was not Administered Prior to Specimen Resection
IDH Family Mutation Analysis Was Not Performed
Norway
IV Anesthesia was not Administered
Additional Surgery for New Metastatic Tumor Event Was Not Performed
No History of Kawasaki Disease
No Known History of Illicit Drug Use
First Degree Family History of Primary Brain Tumor Negative
Minor Criteria for Rheumatic Heart Disease Not Present
Bag
Nitric Oxide Measurement
No History of Neonatal Complication
Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed
MGMT Promoter Methylation Testing Was Not Performed
Device System
Pouch Dosing Unit
NRAS Mutation Analysis Was Not Performed
KRAS Mutation Analysis Was Not Performed
ERBB2 Mutation Analysis Was Not Performed
Documentation Absent
First Degree Family History Thyroid Cancer Negative
RET Rearrangement Analysis Was Not Performed
Regional Anesthesia was not Administered
No History of Non-Cardiac Surgery
KIT Mutation Analysis Was Not Performed
Drug Delivery System
IDH Family Wildtype
Another Form of Birth Control was not Used
digestion
No History of Gestational Complication
Pouch
Stoma
Not Lost to Follow-Up
1p/19q Deletion Analysis Was Not Performed
Preoperative IV Opiates were not Administered
EGFR Amplification Analysis Was Not Performed
numismatics
New Tumor Event After Initial Treatment Absent
Adjuvant Post-operative Radiation Therapy Was Not Administered
MET Mutation Analysis Was Not Performed
Evidence of Disease Absent after Completion of Therapy
Lymph Node Dissection Was Not Performed
MLXIPL wt Allele
ATRX Mutation Analysis Was Not Performed
Chief Complaint was Not Witnessed
Intercurrent Illness is Absent at Onset of Chief Complaint
Preoperative IV Sedation was Not Administered
No Known History of Alcohol Use
digestants
Cancer History Absent
Hypertension Absent
PTEN Mutation Analysis Was Not Performed
Routine Cytogenetics Were not Completed
Negation
Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
No History of Congenital Heart Disease
EGFR Gene Amplification Negative
Twice
Any Metastatic Diagnosis Absent
Family History of Stomach Cancer Absent
Additional Surgery for New Tumor Event Absent
ATRX Gene Mutation Negative
Local Anesthesia Agents were not Administered
Additional Immunohistochemistry Was Not Performed
enterostomy
First Degree Family History Cancer Negative
Intervention Not Given for Kawasaki Disease
Neither Case or Control Status
Nitric Oxide
Adjuvant Post-operative Chemotherapy Was Not Administered
digestive tract function, nos
PTEN Gene Mutation Negative
Has No Sibling
Adjuvant Post-operative Immunological Therapy Was Not Administered
History of Medical Treatment Absent
Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up
Digestion
Preoperative IV Antiemetics were not Administered
Chemotherapy Not Received
No History of Other Muscular Dystrophy or Glycogen Storage Disorder
Regular Smokeless Tobacco Use for Six Weeks or More Negative
Unemployed
Preoperative IV Antacids were not Administered
Other Preoperative IV Medications were not Administered
Adjuvant I-131 Therapy Negative
Radiation Was Not Administered as an Additional Treatment for a New Tumor Event
stoma site, nos
ALK Rearrangement Analysis Was Not Performed
Stomatocyte Count
Medication Not Taken
No History of Myopathy
Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection
Neither
PDGFRA Mutation Analysis Was Not Performed
Additional Surgery for New Loco-Regional Tumor Event Was Not Performed
Drug Delivery System Category
Pouch Dosage Form Category
Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis
Chief Complaint Not Caused by Trauma
Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
NON Mouse
TP53 Mutation Analysis Was Not Performed
Patient was not Postmenopausal with no Prior Oophorectomy
Chemical/Occupational Exposure Absent
coins
SDH Complex Mutation Analysis Was Not Performed
Tumor Reoccurrence Absent After Initial Treatment
Therapeutic Ionizing Radiation to Head History Absent
BRAF Mutation Analysis Was Not Performed
Radiation History Negative
No History of Rheumatic Fever
Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
equipment and supplies, hospital
Physician Diagnosed Diabetes Absent
EGFR Mutation Analysis Was Not Performed
ROS1 Rearrangement Analysis Was Not Performed
History of Colorectal Cancer Negative
Tumor Progression Absent After Initial Treatment
Use of Smokeless Tobacco at Time of Diagnosis Negative
Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Patient was Not Previously Evaluated for Current Chief Complaint
Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered
Radiation Therapy Not Received
New Disease is not Multifocal
BRAF Rearrangement Analysis Was Not Performed
Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered
Additional Molecular Studies Were Not Performed
No Response to Intervention for Kawasaki Disease
Paraneoplastic Syndrome is Not Present
Caffeine Not Routinely Consumed
10q23/PTEN Locus Deletion Analysis Was Not Performed
NF1 Mutation Analysis Was Not Performed
Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed
Fluorescence In Situ Hybridization Was Not Performed

---
https://www.has-sante.fr/jcms/p_3519078/fr/sensura-mio
2024
France
health technology assessment
Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered
KRAS Mutation Analysis Was Not Performed
Nitric Oxide
Additional Surgery for New Tumor Event Absent
Family History of Stomach Cancer Absent
Preoperative IV Sedation was Not Administered
NON Mouse
No History of Neonatal Complication
EGFR Amplification Analysis Was Not Performed
stoma site, nos
ALK Rearrangement Analysis Was Not Performed
equipment and supplies, hospital
Nitric Oxide Measurement
Adjuvant I-131 Therapy Negative
No History of Myopathy
Drug Delivery System Category
digestion
enterostomy
10q23/PTEN Locus Deletion Analysis Was Not Performed
Additional Molecular Studies Were Not Performed
SDH Complex Mutation Analysis Was Not Performed
No History of Gestational Complication
Medication Not Taken
Fluorescence In Situ Hybridization Was Not Performed
No History of Kawasaki Disease
No Known History of Illicit Drug Use
Another Form of Birth Control was not Used
ATRX Mutation Analysis Was Not Performed
BRAF Mutation Analysis Was Not Performed
Piece Unit
Hypertension Absent
BRAF Rearrangement Analysis Was Not Performed
Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
MLXIPL wt Allele
First Degree Family History Thyroid Cancer Negative
First Degree Family History of Primary Brain Tumor Negative
PTEN Gene Mutation Negative
IDH Family Wildtype
Intervention Not Given for Kawasaki Disease
Adjuvant Post-operative Radiation Therapy Was Not Administered
digestant, nos
IV Anesthesia was not Administered
Cancer History Absent
Patient was not Postmenopausal with no Prior Oophorectomy
Lymph Node Dissection Was Not Performed
No History of Congenital Heart Disease
New Disease is not Multifocal
Norway
Documentation Absent
Additional Immunohistochemistry Was Not Performed
New Tumor Event After Initial Treatment Absent
Evidence of Disease Absent after Completion of Therapy
First Degree Family History Cancer Negative
Additional Surgery for New Metastatic Tumor Event Was Not Performed
No Known History of Alcohol Use
Device System
IDH Family Mutation Analysis Was Not Performed
Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
digestants
Adjuvant Post-operative Immunological Therapy Was Not Administered
Neither Case or Control Status
NF1 Mutation Analysis Was Not Performed
Preoperative IV Antiemetics were not Administered
Additional Surgery for New Loco-Regional Tumor Event Was Not Performed
Other Preoperative IV Medications were not Administered
Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed
MET Mutation Analysis Was Not Performed
Tumor Reoccurrence Absent After Initial Treatment
TP53 Mutation Analysis Was Not Performed
Stoma
Not Lost to Follow-Up
History of Medical Treatment Absent
EGFR Gene Amplification Negative
Radiation Therapy Not Received
Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up
Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered
MGMT Promoter Methylation Testing Was Not Performed
Stomatocyte Count
Therapeutic Ionizing Radiation to Head History Absent
Neither
Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
ROS1 Rearrangement Analysis Was Not Performed
No History of Other Muscular Dystrophy or Glycogen Storage Disorder
Paraneoplastic Syndrome is Not Present
KIT Mutation Analysis Was Not Performed
Physician Diagnosed Diabetes Absent
1p/19q Deletion Analysis Was Not Performed
digestive tract function, nos
Exhibit
Radiation Was Not Administered as an Additional Treatment for a New Tumor Event
Preoperative IV Antacids were not Administered
RET Rearrangement Analysis Was Not Performed
Tumor Progression Absent After Initial Treatment
ERBB2 Mutation Analysis Was Not Performed
Drug Delivery System
No History of Rheumatic Fever
Minor Criteria for Rheumatic Heart Disease Not Present
ATRX Gene Mutation Negative
Chemotherapy Not Received
Adjuvant Post-operative Chemotherapy Was Not Administered
NRAS Mutation Analysis Was Not Performed
History of Colorectal Cancer Negative
Digestion
Any Metastatic Diagnosis Absent
Caffeine Not Routinely Consumed
Radiation History Negative
Intercurrent Illness is Absent at Onset of Chief Complaint
PDGFRA Mutation Analysis Was Not Performed
Chemical/Occupational Exposure Absent
Has No Sibling
Chief Complaint was Not Witnessed
PTEN Mutation Analysis Was Not Performed
Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection
Use of Smokeless Tobacco at Time of Diagnosis Negative
Routine Cytogenetics Were not Completed
Interferon Gamma Treatment was not Administered Prior to Specimen Resection
Unemployed
Negation
Patient was Not Previously Evaluated for Current Chief Complaint
Regional Anesthesia was not Administered
No History of Non-Cardiac Surgery
Regular Smokeless Tobacco Use for Six Weeks or More Negative
Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis
Preoperative IV Opiates were not Administered
EGFR Mutation Analysis Was Not Performed
Chief Complaint Not Caused by Trauma
No Response to Intervention for Kawasaki Disease
Local Anesthesia Agents were not Administered
Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed

---
https://www.has-sante.fr/jcms/p_3519081/fr/sensura-mio
2024
France
health technology assessment
numismatics
Drug Delivery System
coins
enterostomy
Device System
Pouch
Stomatocyte Count
Pouch Dosage Form Category
Drug Delivery System Category
digestive system
digestive tract function, nos
Pouch Dosing Unit
Twice
Bag
digestant, nos
equipment and supplies, hospital
MLXIPL wt Allele
Digestion
Stoma
ostomy collection bag

---
https://www.has-sante.fr/jcms/p_3519084/fr/sensura-mio
2024
France
health technology assessment
MLXIPL wt Allele
stoma site, nos
Stomatocyte Count
Drug Delivery System Category
digestant, nos
Drug Delivery System
equipment and supplies, hospital
Exhibit
Digestion
digestive system
enterostomy
Stoma
Piece Unit
digestive tract function, nos
Device System

---
https://cps.ca/fr/documents/position/troubles-des-conduites-alimentaires
2024
Canada
practice guideline
conduct disorder
Handbook
patient care management
pediatrician
Eating Disorder
pediatrics
Pediatric
eating
Pediatric
Charge
Feeding and Eating Disorders
Guide Device
Conduct Disorder

---
https://www.anses.fr/fr/content/ingestion-de-pile-bouton-enfants
2024
France
popular works
ingestion
Minute Unit of Plane Angle
child
button, nos
Child
Count Dosing Unit
child, nos
Financial Account
Battery Device
Per Minute
ingestion
Offspring
Ingestion
eating

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pyzchiva
2024
false
false
false
Netherlands
French
English
Ustekinumab
Ustekinumab
drug approval
europe
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
biosimilar pharmaceuticals
ustekinumab
psoriasis
arthritis, psoriatic
drug interactions
pregnancy
breast feeding
crohn disease
colitis, ulcerative
Product containing only ustekinumab in parenteral dose form (medicinal product form)
infusions, intravenous
Interleukin Inhibitors
Interleukin Inhibitors
Interleukin-12
Interleukin-23
injections, subcutaneous

---
https://www.ema.europa.eu/en/medicines/human/EPAR/emblaveo
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
avibactam
avibactam
aztreonam
aztreonam
anti-bacterial agents
anti-bacterial agents
adult
beta-Lactamase Inhibitors
beta-Lactamase Inhibitors
intraabdominal infections
complicated intra-abdominal infections
Healthcare-Associated Pneumonia
pyelonephritis
Gram-Negative aerobic bacteria
Gram-Negative bacterial infections
infusions, intravenous
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
aztreonam and beta-lactamase inhibitor

---
https://www.ema.europa.eu/en/medicines/human/EPAR/naveruclif
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
paclitaxel
paclitaxel
drugs, generic

---
https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity
2024
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
drug approval
europe
etrasimod
etrasimod
colitis, ulcerative
etrasimod
administration, oral
adult
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Etrasimod Arginine
Etrasimod Arginine
Immunomodulating Agents
Immunomodulating Agents
Sphingosine-1-phosphate Receptor Modulator
Sphingosine-1-phosphate Receptor Modulator

---
https://www.ema.europa.eu/en/medicines/human/EPAR/uzpruvo
2024
false
false
false
Netherlands
French
English
drug approval
europe
Ustekinumab
Ustekinumab
syndication feed
summary of product characteristics
package leaflet
drug evaluation
biosimilar pharmaceuticals

---
https://www.has-sante.fr/jcms/p_3431997/fr/tibsovo-ivosidenib-servier-ivosidenib-leucemie-aigue-myeloide
2024
false
false
false
France
evaluation of the transparency committee
Tibsovo
ivosidenib
ivosidenib
Ivosidenib

---
https://ansm.sante.fr/uploads/2024/06/03/20240603-rs-cortifoam-lettre-patient-importation-cortifoam.pdf
2024
false
false
false
France
French
popular works
drug information
crohn disease
colitis, ulcerative
proctitis
administration, rectal
hydrocortisone acetate
hydrocortisone

---
https://www.has-sante.fr/jcms/p_3527277/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2024
false
false
false
France
evaluation of the transparency committee
Nivolumab
cancer
Malignant Neoplasm
bronchus, nos
neoplasm, malignant
Bronchial
carcinoma, non-small-cell lung
Opdivo
nivolumab
Nivolumab

---
https://www.has-sante.fr/jcms/p_3527216/fr/afinitor-everolimus-tumeurs-neuroendocrines-d-origine-pancreatique
2024
false
false
false
France
pancreatic neoplasms
treatment outcome
insurance, health, reimbursement
disease progression
adult
Metastatic Pancreatic Neuroendocrine Tumor
Unresectable Pancreatic Neuroendocrine Tumor
administration, oral
antineoplastic agents
everolimus
evaluation of the transparency committee
neuroendocrine tumors
Everolimus

---
https://www.santepubliquefrance.fr/regions/occitanie/documents/enquetes-etudes/2024/utilisation-d-un-indicateur-pluviometrique-pour-l-identification-d-un-contexte-favorable-a-la-survenue-d-une-epidemie-de-gastro-enterite-aigue-d-or
2024
France
technical report
acute gastroenteritis, nos
Occurrence
disease outbreaks
Favorable
Off-Label use
CDISC Define-XML Origin Source Terminology
Therapeutic Exploratory Study
gastroenteritis
Indicator
data collection
indication of
Clinical Outcomes Assessment Context of Use
De-Identification
suggestive of
epidemics
enteritis
Enteritis
Epidemic Disorder
CDISC SDTM Gastrointestinal Test Name Terminology

---
https://www.sfed.org/wp-content/uploads/2024/07/RecoSFED-GIFE-personnelparamedical-au-sein-dun-plateau-technique-endo-digestive-24.pdf
2024
France
guideline
digestive tract function, nos
breast
Tray
endoscopy, digestive system
health planning guidelines
Female Breast
Digestion
paramedics
Paramedic
Endoscopic Procedure
allied health personnel
endoscopy of breast, nos
digestant, nos
Male Breast
Murine Breast

---
https://www.canal-u.tv/chaines/ub/jeu-de-maux-episode-1-l-etymologie-la-terminologie-du-suffixe-rrhee-et-la-diarrhee
2024
France
audiovisual aids
CDISC SDTM Model Version 1.6
ECOG Performance Status 1
Thought Score 1
Intensity and Distress 1
terminology as topic
Episode
One Hundred Percent
Gleason Grade Group 1
diarrhea
Mild Adverse Event
1+ Score, WHO
Usual Severity Diarrhea
Diarrhea, CTCAE
One Full Term Pregnancy
Terminology
Upset Score 1
How Much Distress Diarrhea
Nomenclature
One
diarrhoea
diarrhea, nos
CDISC SDTM Model Version 1.5
Clinical Status Ordinal Scale Outcome 1
Tumor Regression Score 1
Symptoms Extent Score 1
Illness Intrusiveness Rating 1
Diarrhea
Severity of Symptom Score 1
episode of
1+ Score
Neck Pain Score 1
Fear Score 1
Agreement Score 1
terminology
Phase I Trial
Never Smoker
etymology

---
https://www.cochrane.org/fr/CD014580/GUT_prise-en-charge-de-la-constipation-refractaire-chez-lenfant
2024
United Kingdom
review of literature
french abstract
Have Constipation
Constipation
Charge
constipation
Constipation, CTCAE
Child Relation
Usual Severity Constipation
child
How Much Distress Constipation
child, nos
obstipation
constipation
patient care management
How Often Constipation
Child Individual
Refractory

---
https://minerva-ebp.be/FR/Article/2382
2024
Belgium
critical appraisal or critical reading
diabetes mellitus, type 2
disease
mortality
What Month is it
has patient
eating, nos
Food, Ultra-Processed
diabetes non-insulin dependent
With Food
Illinois
Patient
Interleukin
Ratio
Type 2 Diabetes Mellitus
patients
Food
food, nos
Regulatory Report
eating
albumin/globulin ratio
Israel
research report

---
https://www.arcagy.org/infocancer/localisations/appareil-digestif/cancer-pancreas.html/
2024
France
popular works
Pancreas
pancreas
Rat Pancreas
Mouse Pancreas
Murine Pancreas
Tail of the Pancreas
Head of the Pancreas
Body of the Pancreas

---
https://www.chu-lyon.fr/etp-mon-tca-les-autres-et-moi
2024
France
patient education handout
ego
partial thromboplastin time
coagulation time, activated
Feeding and Eating Disorders

---
https://www.anses.fr/fr/system/files/NUT2024SA0040-2.pdf
2024
France
technical report
due to
eating
cannabidiol
cannabis sativa
cannabis
leaves, nos
judgment
base, nos
cannabidiol
toilet facilities
infusion, nos
hemp

---
https://www.euro-pharmat.com/content_page/download/9179/6688/235
2024
France
journal article
enteral nutrition
device, nos
nutrition, nos
medical devices
gastrostomy, nos
gastrostomy
equipment and supplies

---
https://www.has-sante.fr/jcms/p_3574980/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal
2024
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
Ipilimumab
Nivolumab
Opdivo
ipilimumab
colorectal neoplasms
yervoy
nivolumab

---
https://www.omedit-centre.fr/medias/Securiser-transport-stockage-insulines.pdf
2024
France
scientific and technical information
insulin
insulins
carrying
Hoarding
lifting

---
https://www.chu-lyon.fr/etp-des-maladies-chroniques-du-foie-hepat-et-moi
2024
France
popular works
chronic disease, nos
education
chronic disease
disease of liver, nos
chronically ill
Program
liver diseases
liver
patient education as topic
patient care planning
therapeutics

---
https://www.chu-lyon.fr/pancreatectomie
2024
France
popular works
pancreatectomy, nos
pancreatectomy

---
https://www.chu-lyon.fr/traitement-par-acide-tranexamique
2024
France
popular works
acid, nos
tranexamic acid

---
https://www.cochrane.org/fr/CD008879/COLOCA_une-alimentation-complementaire-avant-loperation-est-elle-preferable-une-alimentation-normale-chez
2024
false
France
United Kingdom
French
french abstract
meta-analysis
digestive system surgical procedures
preoperative care
dietary supplements
treatment outcome
enteral nutrition
parenteral nutrition
postoperative complications

---
https://www.anses.fr/fr/system/files/NUT2023VIG0188.pdf
2024
France
public health guidelines
Polypodium leucotomos Extract
Hallucinations, CTCAE
dietary supplements
Breast Cancer Anti-Estrogen Resistance Protein 1
True Case Status
eating
Case
Food Consumption
CTNND1 wt Allele
Coronavirus Anxiety Scale
hallucinations
Hallucination
Neither Agree or Disagree
Have Not Tried It
Case Dosing Unit
inlets
Packaging Case
Regulatory Action
triplets
snacks
bays
Relative Value
judgment
BCAR1 wt Allele
hallucination, nos
No Cases Transmission Pattern
Catenin Delta-1

---
https://www.anses.fr/fr/system/files/NUT2024SA0040.pdf
2024
France
public health guidelines
Deriving
Neither Agree or Disagree
Tumor Regression Score 1
Baseline
base, nos
Cannabidiol
One
1+ Score, WHO
Base of the Prostate
Mathematical Derivation
Derivative
One Hundred Percent
Thought Score 1
Nucleotide
judgment
Core Device
eating
Seed
Intensity and Distress 1
Clinical Status Ordinal Scale Outcome 1
Derivation
Derivation Expression
bays
Phase I Trial
Agreement Score 1
Illness Intrusiveness Rating 1
cannabis
CDISC SDTM Model Version 1.6
Mild Adverse Event
Symptoms Extent Score 1
Dental Base
Consumption of Goods
Relative Value
hemp
CDISC SDTM Model Version 1.5
Food Consumption
Never Smoker
Fear Score 1
cannabidiol
Core Specimen
Gleason Grade Group 1
Bypass
grain
Derivation
Mathematical Derivation
Residual
Severity of Symptom Score 1
cannabidiol
cannabis sativa
seeds
1+ Score
Radioactive Seed Implant Dosing Unit
inlets
Neck Pain Score 1
shunt, nos
Derived Flag
One Full Term Pregnancy
Baseline Epoch
ECOG Performance Status 1
Upset Score 1

---
https://www.ce-mir.fr/files/medias/documents/51.%20H%C3%A9morragie%20digestive.pdf
2024
France
educational course
hemorrhage
Digestive System Hemorrhage
gastrointestinal hemorrhage
digestion
digestants
gastrointestinal hemorrhage, nos

---
https://www.ce-mir.fr/files/medias/documents/52.%20Pancr%C3%A9atite%20aigu%C3%AB.pdf
2024
France
educational course
pancreatitis
acute pancreatitis
Acute Pancreatitis

---
https://www.ce-mir.fr/files/medias/documents/53.%20Insuffisance%20h%C3%A9patique%20aigu%C3%AB.pdf
2024
France
educational course
hepatic failure, nos
liver failure, acute
acute insufficiency
Acute Liver Failure

---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/medecine-ladolescent/troubles-conduites-alimentaires-ladolescent
2024
France
educational course
Conduct Disorder
adolescence
Adolescents
Teenager
Eating Disorder
Adolescent
adolescent
Feeding and Eating Disorders
conduct disorder

---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/infectiologie/diarrhee-aigue
2024
France
educational course
diarrhea, nos
Diarrhea, CTCAE
diarrhoea
How Much Distress Diarrhea
Diarrhea
diarrhea
Usual Severity Diarrhea

---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/gastroenterologie-nutrition-chirurgie-abdomino-pelvienne/diarrhee-chronique
2024
France
educational course
diarrhoea
diarrhea
Chronic Graft Versus Host Disease
diarrhea, nos
Diarrhea
Usual Severity Diarrhea
How Much Distress Diarrhea
Diarrhea, CTCAE

---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/gastroenterologie-nutrition-chirurgie-abdomino-pelvienne/constipation
2024
France
educational course
constipation
Have Constipation
constipation
How Often Constipation
Constipation, CTCAE
How Much Distress Constipation
Usual Severity Constipation
constipation
Constipation

---
https://www.has-sante.fr/jcms/p_3530992/fr/enhertu-trastuzumab-deruxtecan-cancer-du-poumon
2024
false
false
false
France
evaluation of the transparency committee
Lung Carcinoma
neoplasm, malignant
Trastuzumab Deruxtecan
lung neoplasms
Trastuzumab Deruxtecan
trastuzumab deruxtecan
lung cancer
trastuzumab
Trastuzumab
trastuzumab deruxtecan

---
https://www.has-sante.fr/jcms/p_3534502/fr/emblaveo-aztreonam/avibactam-infections-graves
2024
false
false
false
France
drug combinations
anti-bacterial agents
treatment outcome
insurance, health, reimbursement
avibactam
Avibactam Sodium
beta-Lactamase Inhibitors
aztreonam
intraabdominal infections
complicated intra-abdominal infections
Complicated intra-abdominal infection
Healthcare-Associated Pneumonia
pneumonia, ventilator-associated
pyelonephritis
urinary tract infections
Gram-Negative bacterial infections
aztreonam and beta-lactamase inhibitor
evaluation of the transparency committee

---
https://ansm.sante.fr/actualites/conduites-a-tenir-dans-un-contexte-mondial-de-fortes-tensions-en-pegasys-peginterferon-alfa-2a
2024
false
false
false
France
French
drug information
guidelines for drug use
peginterferon alfa-2a
peginterferon alfa-2a
peginterferon alfa-2a
onco-hematology
Ropeginterferon Alfa-2B

---
https://ansm.sante.fr/informations-de-securite/ocaliva-acide-obeticholique-recommandation-dabrogation-de-lautorisation-de-mise-sur-le-marche-conditionnelle-dans-lunion-europeenne-en-raison-dun-benefice-clinique-non-confirme
2024
false
false
false
France
French
risk assessment
Benefit-Risk assessment
drug information
obeticholic acid
obeticholic acid
obeticholic acid
Primary Biliary Cholangitis

---
https://www.ameli.fr/assure/sante/themes/douleurs-estomac-gastrite
2024
France
popular works
gastritis
Gastritis
gastritis, nos
pain
Stomach Pain
dyspepsia, nos
stomach
Gastritis, CTCAE

---
https://www.has-sante.fr/jcms/p_3420797/fr/keytruda-pembrolizumab-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
breast neoplasms
pembrolizumab
breast cancer
pembrolizumab
Childhood Breast Carcinoma
Pembrolizumab
neoplasm, malignant
Male Breast Carcinoma
Keytruda
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3535830/fr/cisplatine-hikma-cisplatine-oncologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
cisplatin
infusions, intravenous
antineoplastic agents
testicular neoplasms
ovarian neoplasms
urinary bladder neoplasms
neoplasm metastasis
Squamous Cell Carcinoma of Head and Neck
carcinoma, non-small-cell lung
uterine cervical neoplasms
evaluation of the transparency committee
cisplatin

---
https://www.sfed.org/actualites/dernieres-recommandations-de-lesge-sur-la-prise-en-charge-de-loesophage-de-barrett-les-points-clefs/
2024
France
guideline
french abstract
Point Name
barrett esophagus
barrett's esophagus
patient care management
TIP GCT Study Identifier
Last
KAT5 wt Allele
Charge
Point
health planning guidelines
Barrett Esophagus
TIP Regimen
Tip

---
https://www.pasteur.fr/fr/centre-medical/fiches-maladies/cancers-ulceres-gastriques
2024
France
popular works
stomach ulcer
Gastric Ulcer
gastric ulcer, nos

---
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/aout-2024.html#a2_a1
2024
false
false
false
Canada
French
pregnancy
Pregnant People
pharmacovigilance note
calcium carbonate
antacids
Milk-Alkali syndrome
risk
gastroesophageal reflux
calcium carbonate

---
https://www.cochrane.org/fr/CD015573/INFECTN_traitement-de-lechinococcose-kystique-du-foie-maladie-hydatique
2024
United Kingdom
review of literature
french abstract
echinococcosis of liver, nos
Cystic Echinococcosis
GDC Treatment Frequency Terminology
Treat
Biomaterial Treatment
Under No Medication
echinococcosis
No Treatment for Diabetes
Echinococcosis
Therapy Object
liver diseases
disease of liver, nos
Treatment Epoch
Liver and Intrahepatic Bile Duct Disorder
Treatment Study
Treatment
cystic disease, nos
During Treatment
On Treatment

---
https://www.sfed.org/media/guide-pratique-ecolo-endoscopie-fiche-n8/
2024
France
scientific and technical information
Severity of Symptom Score 8
Albania
Assay Internal Control
internal medicine specialist
Handbook
Environmental
gastroenterology
Pars Interna
Gain of Chromosome 8
Guide Device
Approximate
Splayed
Surrounding
environment
Inner
Eight

---
https://www.has-sante.fr/jcms/p_3538225/fr/ayvakyt-avapritinib-mastocytose-systemique-indolente
2024
false
false
false
France
indolent systemic mastocytosis
treatment outcome
insurance, health, reimbursement
adult
administration, oral
avapritinib
evaluation of the transparency committee
mastocytosis, systemic
avapritinib

---
https://www.srlf.org/article/tazocilline-cefepime-reanimation-qui-fait-mieux
2024
France
critical appraisal or critical reading
Cefepime
Device Properties Domain
Reasoning
What Month is it
Dong Chinese
Resuscitation
Cefepime
Foundation for the Accreditation of Cellular Therapy
Doctor of Osteopathic Medicine
Better than Others
cefepime
resuscitation
Improved
Dominican Republic

---
http://beh.santepubliquefrance.fr/beh/2024/15/2024_15_2.html
2024
France
journal article
epidemics
gastroenteritis
devices
Balance Sheet
french
acute gastroenteritis, nos
france
enteritis
Set, Psychology
equipment and supplies
epidemiological monitoring
device, nos

---
https://sante.gouv.fr/IMG/pdf/dgs-urgent_n2024_15_intoxication_alimentaire_cas_de_botulisme.pdf
2024
France
scientific and technical information
foodborne botulism
botulism
snacks
botulism
food poisoning
food poisoning, nos

---
https://www.afsos.org/wp-content/uploads/2024/09/AFSOS-referentiel-NVAI_0824.pdf
2024
false
false
false
France
antineoplastic agents
chemotherapy-induced nausea and vomiting
antiemetics
algorithms
nausea
guideline

---
https://www.has-sante.fr/jcms/p_3539509/fr/velsipity-etrasimod-rectocolite-hemorragique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
etrasimod
Immunomodulating Agents
Sphingosine-1-Phosphate Receptors
adult
adolescent
administration, oral
evaluation of the transparency committee
colitis, ulcerative
etrasimod

---
https://www.has-sante.fr/jcms/p_3539141/fr/simponi-golimumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
golimumab
injections, subcutaneous

---
https://www.has-sante.fr/jcms/p_3539111/fr/humira-adalimumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
adalimumab
Adalimumab
injections, subcutaneous

---
https://www.has-sante.fr/jcms/p_3540254/fr/lonsurf-trifluridine/tipiracil-cancer-colorectal
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
trifluridine tipiracil drug combination
administration, oral
trifluridine, combinations
Colorectal cancer metastatic
evaluation of the transparency committee
colorectal neoplasms

---
https://www.has-sante.fr/jcms/p_3539090/fr/remsima-infliximab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
Infliximab
injections, subcutaneous
chronic disease
biological therapy

---
https://ansm.sante.fr/actualites/vitamine-b12-injectable-et-buvable-preferez-les-comprimes-aux-ampoules-pour-lusage-par-voie-orale
2024
false
false
false
France
French
drug information
guideline
injections, intramuscular
administration, oral
vitamin B 12
Malabsorption of Vitamin B12
vitamin b 12 deficiency
cyanocobalamin
-
-

---
https://ansm.sante.fr/tableau-marr/trastuzumab-deruxtecan
2024
false
false
false
France
French
risk management
trastuzumab deruxtecan
trastuzumab deruxtecan
infusions, intravenous
Antineoplastic Agents, Immunological
medication errors
guidelines for drug use
lung diseases
patient education handout
patients guideline
trastuzumab deruxtecan
Antineoplastic Agents, Immunological

---
http://beh.santepubliquefrance.fr/beh/2024/16-17/2024_16-17_5.html
2024
France
journal article
french
hepatitis B
dataset
mandatory reporting
organization and administration
acute hepatitis, nos
france
type b viral hepatitis

---
https://www.cochrane.org/fr/CD014869/LIVER_quels-sont-les-benefices-et-les-risques-du-tamoxifene-dans-le-traitement-des-personnes-atteintes-dun
2024
United Kingdom
review of literature
french abstract
disease
tamoxifen
persons
carcinoma, hepatocellular
risk assessment
tamoxifen
hepatocellular carcinoma, nos
risks and benefits
disease of liver, nos

---
https://www.cochrane.org/fr/CD011929/LIVER_quelle-est-la-precision-du-score-fib-4-et-de-lindice-de-forns-tests-non-invasifs-pour-diagnostiquer
2024
United Kingdom
review of literature
french abstract
cicatrix
hepatitis C, chronic
cues
non-invasive
viral hepatitis c
diagnostic tests
disease
adult
adulthood
fibrosis, liver
healing scar
diagnostic tests, routine
cicatrization
liver
hepatic fibrosis, nos
liver cirrhosis
chronic hepatitis, nos

---
https://www.anses.fr/fr/content/medicament-cheval-attention-risque-ingestion
2024
France
popular works
pharmaceutical preparations
eating
attention, nos
homo sapiens
horse diseases
risk
attention
ingestion
drug, nos
ingestion
pituitary dependent hypercortisolism
humans
pituitary acth hypersecretion
equine species

---
https://www.has-sante.fr/jcms/p_3546684/fr/keytruda-pembrolizumab-carcinome-urothelial
2024
false
false
false
France
urologic neoplasms
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
enfortumab vedotin
adult
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
pembrolizumab
evaluation of the transparency committee
carcinoma
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3546934/fr/keytruda-pembrolizumab-cancer-du-rein-en-adjuvant
2024
false
false
false
France
Clear Cell Renal Cell Carcinoma
carcinoma, renal cell
treatment outcome
insurance, health, reimbursement
adult
Antineoplastic Agents, Immunological
pembrolizumab
Adjuvant Therapy
nephrectomy
risk
recurrence
evaluation of the transparency committee
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3546280/fr/ultravist-iopromide-produit-de-contraste-iode
2024
false
false
false
France
iopromide
neoplasm staging
Tumor Size Measurement
breast neoplasms
evaluation of the transparency committee
iopromide
contrast media

---
https://ansm.sante.fr/tableau-marr/etrasimod
2024
false
false
false
France
French
risk management
administration, oral
etrasimod
continuity of patient care
guidelines for drug use
patient education handout
pregnancy
patients guideline
Upfront Treatment
Drug Exposure
etrasimod
Etrasimod Arginine

---
https://minerva-ebp.be/FR/Article/2401
2024
Belgium
critical appraisal or critical reading
diet
dietary supplements
iron, nos
diet, nos
absorption
eating
iron, dietary

---
https://ansm.sante.fr/actualites/campagne-vaccinale-contre-les-infections-a-papillomavirus-humains-hpv-les-dernieres-donnees-confirment-de-nouveau-le-profil-de-securite-du-vaccin-gardasil-9
2024
false
false
false
France
French
papillomavirus infections
vaccination
papillomavirus vaccines
papillomavirus vaccines
drug information
pharmacovigilance
safety management
patient safety
papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52,58)

---
https://www.has-sante.fr/jcms/p_3550669/fr/diagnostic-et-prise-en-charge-de-la-maladie-coeliaque-chez-l-enfant-et-l-adulte-note-de-cadrage
2024
France
practice guideline
disease management
celiac disease
child, nos
adult disease, nos
celiac disease
diagnosis
adult
adult children
no diagnosis
child

---
https://www.anses.fr/fr/content/microbiote-intestinal-des-porcs-et-poulets
2024
France
scientific and technical information
bacterium, nos
chicken, nos
intestinal tract, nos
bacteria
health
intestines
Gastrointestinal Microbiome
homo sapiens
swine
humans
chickens
microbiota

---
https://www.has-sante.fr/jcms/p_3552796/fr/kaftrio-ivacaftor-/-tezacaftor-/-elexacaftor-en-association-avec-kalydeco-ivacaftor-mucoviscidose-enfant-6-ans
2024
false
false
false
France
drug therapy, combination
drug combinations
treatment outcome
insurance, health, reimbursement
elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor
tezacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508
ivacaftor, tezacaftor and elexacaftor
ivacaftor
administration, oral
evaluation of the transparency committee
elexacaftor
child
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3554585/fr/livmarli-maralixibat-cholestase-intrahepatique-progressive-familiale
2024
false
false
false
France
Maralixibat Chloride
maralixibat chloride
treatment outcome
insurance, health, reimbursement
infant
Progressive familial intrahepatic cholestasis
guidelines for drug use
administration, oral
evaluation of the transparency committee
cholestasis, intrahepatic
maralixibat

---
https://www.has-sante.fr/jcms/p_3555565/fr/imfinzi-durvalumab-carcinome-hepatocellulaire-chc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
durvalumab
evaluation of the transparency committee
carcinoma, hepatocellular
durvalumab

---
https://www.inspq.qc.ca/publications/3572
2024
Canada
technical report
Clostridioides difficile
quebec
diarrhoea
diarrhea
diarrhea, nos

---
https://www.cochrane.org/fr/CD015033/LIVER_quels-sont-les-avantages-et-les-risques-de-la-vitamine-e-dans-la-steatose-hepatique-non-alcoolique
2024
United Kingdom
review of literature
french abstract
vitamin e
Non-alcoholic Fatty Liver Disease
vitamin E
alcoholic fatty liver
risk

---
https://www.usherbrooke.ca/baladocritique/archives/episode-65-etude-revise
2024
Canada
sound
ventilation, mechanical
episode of
data collection
ulcer
stress ulcer, nos
mechanical ventilation, nos
prophylactic treatment, nos
stress, physiological
respiration, artificial

---
https://dumas.ccsd.cnrs.fr/dumas-04750398
2024
France
dissertations, academic
Feeding and Eating Disorders
sensitivity and specificity
specificity
conduct disorder
minors

---
https://www.cochrane.org/fr/CD009022/COLOCA_y-t-il-une-difference-dans-les-resultats-lorsquun-chirurgien-pratique-une-seule-incision-plutot-que
2024
United Kingdom
review of literature
french abstract
appendicitis, nos
Surgeons
operative procedure, nos
Professional Practice Gaps
general surgeon, nos
Minimally Invasive Surgical Procedures
kidnapping
incision, nos
appendicitis
incisor
snacks
appendix
crime
resulting in
appendicitis

---
https://www.inserm.fr/actualite/maladie-du-foie-gras-un-effet-protecteur-des-amibes-intestinales/
2024
France
popular works
intestinal tract, nos
amoeba
liver diseases
disease of liver, nos
fatty liver
intestines

---
https://www.cochrane.org/fr/CD016278/CENTRALED_quels-sont-les-benefices-et-les-risques-de-lacide-tranexamique-pour-prevenir-les-saignements
2024
United Kingdom
review of literature
french abstract
acid, nos
cesarean section, nos
risk assessment
tranexamic acid
hemorrhage, nos
risks and benefits
bloodletting
attentiveness
cesarean section
hemorrhage
birth, nos
parturition

---
https://www.has-sante.fr/jcms/p_3418145/fr/livmarli-maralixibat-syndrome-d-alagille
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
maralixibat chloride
infant
child
Cholestatic pruritus (disorder)
administration, oral
orphan drug production
evaluation of the transparency committee
maralixibat
alagille syndrome

---
https://www.has-sante.fr/jcms/p_3418037/fr/imfinzi-durvalumab-carcinome-hepato-cellulaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
tremelimumab
durvalumab
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
infusions, intravenous
evaluation of the transparency committee
durvalumab
carcinoma, hepatocellular

---
https://www.has-sante.fr/jcms/p_3417971/fr/opdivo-nivolumab-adenocarcinome-gastrique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Advanced Gastric Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
adenocarcinoma of esophagus
esophageal neoplasms
Advanced Esophageal Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
HER2/Neu Negative
PD-L1 Positive
infusions, intravenous
nivolumab
evaluation of the transparency committee
adenocarcinoma
Nivolumab
stomach neoplasms

---
https://www.cochrane.org/fr/CD013328/INFECTN_interventions-visant-ameliorer-lassainissement-pour-prevenir-la-diarrhee
2023
United Kingdom
review of literature
french abstract
sanitation
diarrhea
diarrhea, nos
diarrhoea
Diarrhea
attentiveness

---
Nous contacter.
30/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.